Login
$IRD
$3.32 -$0.15 (4.32%) Close

Company Executives

$IRD Management Team

Mr. Robert Gagnon

Chief Financial Officer

Principal Accounting Officer

Age 51
Compensation -
Sex Male

Mr. Cam Gallagher

Independent Chairman of the Board

Age 54
Compensation $174.6K USD
Sex Male

Dr. Benjamin Yerxa

President

Director

Age 58
Compensation -
Sex Male

Dr. George Magrath

Chief Executive Officer

Director

Age 39
Compensation $2.667M USD
Sex Male

Mr. Joseph Schachle

Chief Operating Officer

Age 59
Compensation -
Sex Male

Mr. Bernhard Hoffmann

Senior Vice President - Corporate Development and Operations

Age 68
Compensation $789.9K USD
Sex Male

Dr. Ash Jayagopal

Chief Scientific and Development Officer

Age 42
Compensation -
Sex Male

Mr. Ronil Patel

Chief Business Officer

Age -
Compensation $1.102M USD
Sex Male
Directors
9
serving now
Independent
6 of 6
stated in the proxy; 3 not stated
Average tenure
4.3 years
from year joined
CEO also chairs the board
No
Cam Gallagher
Director Age On board Independent Committees Other public boards 2025 pay Source
Sean Ainsworth
58 2020
6 years
Independent
Audit
None stated $210,137
Dr. Jean Bennett
71 2024
2 years
Not stated None stated REGENXBIO, Inc. $168,503
Susan K. Benton
61 2020
6 years
Independent
Compensation
None stated $180,137
Cam Gallagher
56 2020
6 years
Independent
Compensation · Chair
None stated $295,967
Dr. Adrienne Graves
72 2024
2 years
Independent
Nominating and Corporate Governance
Ocular Therapeutix, Inc., Harrow, Inc. $171,443
Dr. George Magrath
42 2023
3 years
Not stated None stated None stated Paid as CEO
Dr. James S. Manuso
77 2020
6 years
Independent
Nominating and Corporate Governance · Chair
TuHura Biosciences, Inc. $188,917
Richard Rodgers
59 2020
6 years
Independent
Audit · Chair
Ardelyx, Inc., Novavax, Inc. $189,450
Dr. Benjamin R. Yerxa
60 2024
2 years
Not stated None stated Clearside Biomedical, Inc. Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

8 disclosed in the proxy filed Mar 23, 2026
Dr. Pepose
former director of the Company
$0.5 million
fiscal year 2025

Consulting agreement under which Dr. Pepose was paid a monthly consulting fee and received 32,000 RSUs and options to purchase 48,000 shares; the Company incurred related consulting expenses in fiscal year 2025

Amount not stated
March 21, 2025

Subscription agreement to purchase 392,157 shares of Common Stock and receive 392,157 warrants in a private offering

Amount not stated
March 21, 2025

Subscription agreement to purchase 784,314 shares of Common Stock and receive 784,314 warrants in a private offering

Cam Gallagher
Chair of the Company’s Board
$1.0 million

Investment of $1.0 million in the August 2025 Private Placement

Sean Ainsworth
the lead independent director of the Board
$0.1 million

Participation in the August 2025 Private Placement with an investment of $0.1 million

Foundation Fighting Blindness
significant stockholder of the Company
A total of $2.0 million
2022

2022 binding letter agreement to collaborate on natural history studies, requiring the Company to provide a total of $2.0 million of funding, superseded in 2025

With Jaeb Center for Health Research Open in proxy
Foundation Fighting Blindness
significant stockholder of the Company
$0.3 million
fiscal year 2025

2025 letter agreement to collaborate on a study of retinal dystrophies; the Company paid $0.3 million in fiscal year 2025 and must fund one more installment of $0.3 million

With Jaeb Center for Health Research Open in proxy
Retinal Degeneration Fund
sole member is Foundation Fighting Blindness
Up to $2.0 million
June 2025

Funding agreement providing nondilutive funding of up to $2.0 million for the MERTK Program, with $1.0 million disbursed in June 2025, and royalty and milestone payment obligations to RDF

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support